News

Day One Announces Proposed Public Offering of Common Stock

SOUTH SAN FRANCISCO, Calif., June 14, 2022 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals, Inc. (Nasdaq: DAWN), a clinical-stage biopharmaceutical company…

2 years ago

Spectral and Dialco Announce Dr. John Kellum to be Featured as Keynote Lecturer at the 40th Vicenza Course on AKI and CRRT 2022

Dr. Kellum Invited to Participate on Additional Featured PanelsTORONTO, June 14, 2022 (GLOBE NEWSWIRE) -- Spectral Medical Inc. (“Spectral” or…

2 years ago

The Biogen Foundation and Community Lab Celebrates 20 Years of Serving our Communities

The Biogen Foundation has granted $70 million to help underserved communities in advancing science education, health equity, and food securityMore…

2 years ago

Clearside Biomedical Expands Leadership Team with Appointment of Susan Coultas, Ph.D., as Chief Clinical Officer

- Seasoned Life Science Executive Brings Expertise in Ophthalmic Clinical Development, Including Advancement of Multiple Late-Stage Programs to Product Approval…

2 years ago

Trevena Announces the Publication of an Expert Review on the Clinical Profile of OLINVYK® in Post-Operative Care

CHESTERBROOK, Pa., June 14, 2022 (GLOBE NEWSWIRE) -- Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and…

2 years ago

Freeline Initiates Dosing of Second Cohort in B-LIEVE Dose Confirmation Trial of FLT180a in Hemophilia B

Initial cohort one data suggest predictable and sustained Factor IX normalization, supporting additional dosing at the same low dose with…

2 years ago

Sio Gene Therapies Announces Fiscal Year 2021 Year-End Financial Results

NEW YORK and DURHAM, N.C., June 14, 2022 (GLOBE NEWSWIRE) -- Sio Gene Therapies Inc. (NASDAQ: SIOX) today provided financial…

2 years ago

Ocugen Named Among Philadelphia’s ‘2022 Best Places to Work’

MALVERN, Pa., June 14, 2022 (GLOBE NEWSWIRE) -- Ocugen, Inc. (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and…

2 years ago

Clover Doses First Patient with SCB-219M in Phase 1 Trial for Chemotherapy-Induced Thrombocytopenia

-- Phase 1 study to evaluate the safety, tolerability, pharmacokinetics and efficacy of SCB-219M in cancer patients with chemotherapy-induced thrombocytopenia,…

2 years ago

Bavarian Nordic Enters Vaccine Supply Contract with the European Health Emergency Preparedness and Response Authority (HERA) in Response to Monkeypox Outbreak

HERA has ordered 110,000 doses of the Company’s MVA-BN smallpox/monkeypox vaccine for donation to Member StatesDeliveries will start immediately and…

2 years ago